Disease · MONDO_0005061
lung adenocarcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. lung adenocarcinoma. Diseases, record MONDO_0005061. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005061
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- LUAD, adenocarcinoma of lung, adenocarcinoma of the lung, bronchogenic lung adenocarcinoma, non-small cell lung adenocarcinoma, nonsmall cell adenocarcinoma
- Open Targets
Drugs96
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PEMETREXED | CHEMBL225072 | Small molecule | Phase 3 | ClinicalTrials.gov | 23 | 23 | 23 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 18 | 18 | 18 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 13 | 13 | 13 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 3 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets |
| AFATINIB | CHEMBL1173655 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| GEFITINIB | CHEMBL939 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| ICOTINIB | CHEMBL2087361 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
1 to 10 of 96
See all 96 drugsTargets200
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 15 | Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| ERBB2 | Epidermal growth factor receptor | 7 | Epidermal growth factor receptor inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 3 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 7 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 7 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 5 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 5 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| ALK | ALK tyrosine kinase receptor | 4 | ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor | Phase 3 | https://conductscience.org/library/genes/238 | Drugs and targets |
| ERBB4 | Epidermal growth factor receptor | 4 | Epidermal growth factor receptor inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | Phase 3 | https://conductscience.org/library/genes/2066 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 4 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 4 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
1 to 10 of 200
See all 200 targetsTrials133
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00656136 | BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1) | Phase 3 | 585 | 2013-11-27 | Carcinoma, Non-Small-Cell Lung | AFATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01121393 | BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) | Phase 3 | 364 | 2015-01-26 | Carcinoma, Non-Small-Cell Lung, Adenocarcinoma | AFATINIB, CISPLATIN, GEMCITABINE | Its record names the disease | ClinicalTrials.gov |
| NCT00949650 | BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation | Phase 3 | 345 | 2013-11-19 | Carcinoma, Non-Small-Cell Lung, Adenocarcinoma | AFATINIB, CISPLATIN, PEMETREXED | Its record names the disease | ClinicalTrials.gov |
| NCT01466660 | LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung | Phase 2 | 319 | 2017-06-19 | Lung Neoplasms | AFATINIB, GEFITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01803282 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | Phase 1 | 236 | 2020-05-04 | Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer, Breast Cancer | ANDECALIXIMAB, BEVACIZUMAB, CARBOPLATIN, FLUOROURACIL, GEMCITABINE, IRINOTECAN, LEUCOVORIN CALCIUM, OXALIPLATIN, PACLITAXEL, PEMETREXED | Its record names the disease | ClinicalTrials.gov |
| NCT01404260 | Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer | Phase 3 | 219 | 2017-01-27 | Non-small Cell Lung Cancer | CARBOPLATIN, GEFITINIB, GEMCITABINE | Its record names the disease | ClinicalTrials.gov |
| NCT00126581 | Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | Phase 2 | 188 | 2014-04-23 | Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Malignant Pericardial Effusion, Malignant Pleural Effusion, Minimally Invasive Lung Adenocarcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7 | CARBOPLATIN, ERLOTINIB, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT01218516 | A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung | Phase 2 | 130 | 2020-08-20 | Adenocarcinoma of the Lung | FARLETUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01565538 | Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma | Phase 2 | 123 | 2014-09-15 | Lung Cancer | ERLOTINIB, PEMETREXED | Its record names the disease | ClinicalTrials.gov |
| NCT00818441 | Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung | Phase 2 | 119 | 2016-06-01 | Carcinoma, Non-small Cell | DACOMITINIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 133
See all 133 trialsComparisons in its trials23
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Afatinib 50 mg/Day vs Placebo: serious adverse events | 136 of 390 | 36 of 195 | 585 | NCT00656136 | Trial comparisons |
| Afatinib 40 Milligram (mg) vs Gemcitabine / Cisplatin Chemotherapy: deaths from any cause | 16 of 239 | 3 of 113 | 352 | NCT01121393 | Trial comparisons |
| Afatinib 40 Milligram (mg) vs Gemcitabine / Cisplatin Chemotherapy: serious adverse events | 40 of 239 | 12 of 113 | 352 | NCT01121393 | Trial comparisons |
| Afatinib 40 mg vs Pemetrexed/Cisplatin Chemotherapy: serious adverse events | 72 of 229 | 25 of 111 | 340 | NCT00949650 | Trial comparisons |
| Afatinib vs Gefitinib: deaths from any cause | 126 of 160 | 132 of 159 | 319 | NCT01466660 | Trial comparisons |
| Afatinib vs Gefitinib: serious adverse events | 75 of 160 | 64 of 159 | 319 | NCT01466660 | Trial comparisons |
| Arm A vs Arm B: serious adverse events | 14 of 109 | 5 of 110 | 219 | NCT01404260 | Trial comparisons |
| Arm A: Erlotinib vs Arm B: Erlotinib/Carboplatin/Paclitaxel: Number of Participants With Grade 3, 4 or 5 Adverse Event at Least Possibly Related to Treatment. | 20 of 81 | 52 of 99 | 180 | NCT00126581 | Trial comparisons |
| Arm A: Erlotinib vs Arm B: Erlotinib/Carboplatin/Paclitaxel: serious adverse events | 21 of 81 | 39 of 99 | 180 | NCT00126581 | Trial comparisons |
Aflibercept 4.0 mg/kg Arm Assessed by Modified RECIST vs Aflibercept 4.0 mg/kg Arm Assessed by RECIST: Confirmed Objective Response (OR) Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Independent Review Committee (IRC). | 0 of 84 | 0 of 84 | 168 | NCT00284141 | Trial comparisons |
1 to 10 of 23
See all 23 comparisons in its trialsPapers from its trials132
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005061
GET https://conductscience.org/api/diseases/v1/MONDO_0005061/drugs?page=2